Molecular Partners AG
MOLN
Peringkat dalam Saham
#19816
Molecular Partners AG is a clinical-stage biopharmaceutical firm dedicated to... Molecular Partners AG is a clinical-stage biopharmaceutical firm dedicated to discovering, developing, and bringing to market novel therapeutic proteins. Leveraging its proprietary DARPin® platform, the company is advancing a diverse pipeline of product candidates. Key among these is Abicipar, a DARPin-based treatment currently in Phase III clinical development for significant ophthalmic conditions like neovascular wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Additionally, their portfolio features multi-specific DARPin candidates targeting infectious diseases, such as MP0420 and MP0423, both designed to combat the SARS-CoV-2 virus (COVID-19). In the oncology space, Molecular Partners is advancing several programs: MP0310, in Phase Ia for immuno-oncology; MP0317, a Phase I tumor-localized immune agonist engineered to activate immune cells within tumors; and MP0274, also in Phase I, aimed at HER2-positive cancers. Further early-stage assets include MP0533, a CD3 T cell candidate for acute myeloid leukemia, and MP0250, which targets vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and human serum albumin (HSA) to enhance therapeutic half-life. The company actively collaborates with leading pharmaceutical companies. Notable alliances include a partnership with Novartis AG for the development, manufacturing, and commercialization of DARPin-conjugated radioligand therapies; agreements with Amgen SA and Allergan, Inc.; and a discovery alliance in ophthalmology with AbbVie Inc. They also maintain relationships with various other third-party collaborators. Established in 2004, Molecular Partners AG is headquartered in Schlieren, Switzerland.
Harga Saham
$3.69
Kapitalisasi Pasar
$141.31M
Perubahan (1 hari)
-7.00%
Perubahan (1 tahun)
3.11%
Negara
CH
Perdagangan Molecular Partners AG (MOLN)
Kategori
Healthcare
Riwayat pemecahan saham untuk Molecular Partners AG (MOLN)
Saham Molecular Partners AG (simbol: MOLN) telah mengalami total 0 kali pemecahan saham.
Pemecahan saham terbaru terjadi pada Oct 21, 2026.
Satu lembar saham MOLN yang dibeli sebelum Oct 21, 2026 sekarang setara dengan 0 lembar saham MOLN.
Pemecahan saham terbaru terjadi pada Oct 21, 2026.
Satu lembar saham MOLN yang dibeli sebelum Oct 21, 2026 sekarang setara dengan 0 lembar saham MOLN.
Daftar pemecahan saham
| Tahun | Pemecahan | Kelipatan | Kelipatan Kumulatif |
|---|---|---|---|
| Tidak cukup data untuk tanggal yang disediakan. | |||
Pemecahan saham untuk perusahaan sejenis atau pesaing
| Perusahaan | Jumlah pemecahan saham | Kelipatan Kumulatif | Negara |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
NL
|
|
| 0 | - |
CH
|
